Loading...

Recro Pharma

BST:RAH
Snowflake Description

Reasonable growth potential with worrying balance sheet.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
RAH
BST
$184M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Recro Pharma, Inc., a specialty pharmaceutical company, develops and commercializes products for hospital and related acute care settings. The last earnings update was 61 days ago. More info.


Add to Portfolio Compare Print
  • Recro Pharma has significant price volatility in the past 3 months.
RAH Share Price and Events
7 Day Returns
-1.9%
BST:RAH
-2.4%
DE Biotechs
1.8%
DE Market
1 Year Returns
-20.8%
BST:RAH
-10.2%
DE Biotechs
-6%
DE Market
RAH Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Recro Pharma (RAH) -1.9% -14.2% 4.9% -20.8% 17.3% 52.2%
DE Biotechs -2.4% 3.2% -7.7% -10.2% 51.2% 10.1%
DE Market 1.8% 4.6% 7.4% -6% 10.1% 15.3%
1 Year Return vs Industry and Market
  • RAH underperformed the Biotechs industry which returned -10.2% over the past year.
  • RAH underperformed the Market in Germany which returned -6% over the past year.
Price Volatility
RAH
Industry
5yr Volatility vs Market
Related Companies

Value

 Is Recro Pharma undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Recro Pharma to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Recro Pharma.

BST:RAH Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 5 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 9.6%
Perpetual Growth Rate 10-Year DE Government Bond Rate 0.2%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for BST:RAH
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate 0.2%
Equity Risk Premium S&P Global 6%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.45
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.448 (1 + (1- 21%) (34.94%))
1.568
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.57
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.23% + (1.568 * 5.96%)
9.57%

Discounted Cash Flow Calculation for BST:RAH using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Recro Pharma is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

BST:RAH DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 9.57%)
2019 -27.60 Analyst x1 -25.19
2020 18.80 Analyst x1 15.66
2021 15.20 Analyst x1 11.55
2022 12.96 Est @ -14.76% 8.99
2023 11.63 Est @ -10.27% 7.36
2024 10.80 Est @ -7.12% 6.24
2025 10.27 Est @ -4.91% 5.41
2026 9.92 Est @ -3.37% 4.78
2027 9.69 Est @ -2.29% 4.26
2028 9.54 Est @ -1.54% 3.83
Present value of next 10 years cash flows $42.89
BST:RAH DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= $9.54 × (1 + 0.23%) ÷ (9.57% – 0.23%)
$102.39
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $102.39 ÷ (1 + 9.57%)10
$41.04
BST:RAH Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $42.89 + $41.04
$83.93
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $83.93 / 21.99
$3.82
BST:RAH Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in BST:RAH represents 0.86316x of NasdaqCM:REPH
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.86316x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (USD) x Listing Adjustment Factor
= $ 3.82 x 0.86316
€3.29
Value per share (EUR) From above. €3.29
Current discount Discount to share price of €7.22
= -1 x (€7.22 - €3.29) / €3.29
-119%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

  • The current share price of Recro Pharma is above its future cash flow value.
Often investors are willing to pay a premium for a company that has a high dividend or the potential for future growth.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Recro Pharma's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Recro Pharma's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
BST:RAH PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $-3.90
NasdaqCM:REPH Share Price ** NasdaqCM (2019-04-18) in USD $8.36
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.44x
Germany Market PE Ratio Median Figure of 424 Publicly-Listed Companies 19.59x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Recro Pharma.

BST:RAH PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqCM:REPH Share Price ÷ EPS (both in USD)

= 8.36 ÷ -3.90

-2.15x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Recro Pharma is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Recro Pharma is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Recro Pharma's expected growth come at a high price?
Raw Data
BST:RAH PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -2.15x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 5 Analysts
77.4%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.3x
Germany Market PEG Ratio Median Figure of 270 Publicly-Listed Companies 1.56x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Recro Pharma, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Recro Pharma's assets?
Raw Data
BST:RAH PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $-0.89
NasdaqCM:REPH Share Price * NasdaqCM (2019-04-18) in USD $8.36
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.71x
Germany Market PB Ratio Median Figure of 574 Publicly-Listed Companies 1.84x
BST:RAH PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqCM:REPH Share Price ÷ Book Value per Share (both in USD)

= 8.36 ÷ -0.89

-9.35x

* Primary Listing of Recro Pharma.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Recro Pharma has negative assets, we can't compare the value of its assets to the DE Biotechs industry average.
X
Value checks
We assess Recro Pharma's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Recro Pharma has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Recro Pharma expected to perform in the next 1 to 3 years based on estimates from 5 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
77.4%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Recro Pharma expected to grow at an attractive rate?
  • Recro Pharma's earnings growth is expected to exceed the low risk savings rate of 0.2%.
Growth vs Market Checks
  • Recro Pharma's earnings growth is expected to exceed the Germany market average.
  • Recro Pharma's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
BST:RAH Future Growth Rates Data Sources
Data Point Source Value (per year)
BST:RAH Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 5 Analysts 77.4%
BST:RAH Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 5 Analysts 12.9%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.5%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.6%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
BST:RAH Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
BST:RAH Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 163 20 2
2022-12-31 122 -7 3 3
2021-12-31 106 -7 -3 4
2020-12-31 99 6 -4 5
2019-12-31 86 -27 -42 4
BST:RAH Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 77 -43 -80
2018-09-30 79 -34 -63
2018-06-30 77 -30 -58
2018-03-31 73 -25 -54
2017-12-31 72 -17 -50
2017-09-30 70 -17 -36
2017-06-30 70 -9 -33
2017-03-31 70 -8 -32
2016-12-31 69 -3 -30
2016-09-30 69 -4 -9
2016-06-30 68 1 -6
2016-03-31 70 9 1

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Recro Pharma's earnings are expected to grow significantly at over 20% yearly.
  • Recro Pharma's revenue is expected to grow by 12.9% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
BST:RAH Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below

All data from Recro Pharma Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

BST:RAH Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 0.94 1.24 0.68 3.00
2022-12-31 0.81 1.00 0.65 3.00
2021-12-31 -0.02 0.78 -2.04 4.00
2020-12-31 -0.56 0.59 -1.84 4.00
2019-12-31 -2.19 -1.51 -2.66 4.00
BST:RAH Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 -3.90
2018-09-30 -3.15
2018-06-30 -3.00
2018-03-31 -2.85
2017-12-31 -2.63
2017-09-30 -2.07
2017-06-30 -2.10
2017-03-31 -2.41
2016-12-31 -2.82
2016-09-30 -0.94
2016-06-30 -0.64
2016-03-31 0.07

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Recro Pharma will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Recro Pharma's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Recro Pharma has a total score of 4/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Recro Pharma performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Recro Pharma's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Recro Pharma does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Recro Pharma's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Recro Pharma's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Recro Pharma's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Recro Pharma Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

BST:RAH Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 77.35 -79.72 36.88
2018-09-30 78.61 -62.51 37.88
2018-06-30 77.44 -58.31 37.55
2018-03-31 72.63 -54.45 30.91
2017-12-31 71.83 -50.08 25.43
2017-09-30 70.15 -36.40 20.47
2017-06-30 69.99 -32.72 17.68
2017-03-31 70.34 -31.75 14.12
2016-12-31 69.34 -30.21 12.74
2016-09-30 68.73 -9.17 13.79
2016-06-30 68.31 -5.94 13.45
2016-03-31 69.69 0.63 13.29
2015-12-31 51.95 3.03 13.02
2015-09-30 35.20 -11.08 9.72
2015-06-30 18.66 -13.64 7.38
2015-03-31 -15.12 5.74
2014-12-31 -17.40 4.00
2014-09-30 -14.42 2.86 0.06
2014-06-30 -10.32 1.86 0.18
2014-03-31 -8.30 1.10 0.43
2013-12-31 -2.40 0.55 0.54
2013-09-30 -2.26 0.56 0.52
2013-06-30 -2.12 0.50 0.47
2013-03-31 -1.90 0.36 0.44
2012-12-31 -1.95 0.34 0.54

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Recro Pharma has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) due to its liabilities exceeding its assets.
  • It is difficult to establish if Recro Pharma has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Recro Pharma improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Recro Pharma's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Recro Pharma has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Recro Pharma's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Recro Pharma's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Recro Pharma is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Recro Pharma's long term commitments exceed its cash and other short term assets.
Balance sheet
This treemap shows a more detailed breakdown of Recro Pharma's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Recro Pharma has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Recro Pharma Company Filings, last reported 3 months ago.

BST:RAH Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 -19.50 64.24 38.51
2018-09-30 13.55 54.68 37.03
2018-06-30 24.49 54.32 48.91
2018-03-31 24.58 53.96 51.27
2017-12-31 28.85 53.60 64.48
2017-09-30 49.65 24.89 41.31
2017-06-30 56.99 24.71 50.25
2017-03-31 64.36 24.55 55.55
2016-12-31 71.61 24.39 64.48
2016-09-30 40.63 24.24 24.75
2016-06-30 31.31 27.58 14.85
2016-03-31 35.04 27.42 14.92
2015-12-31 40.35 29.76 19.78
2015-09-30 28.38 38.02 28.28
2015-06-30 14.73 45.62 15.69
2015-03-31 15.31 0.00 16.59
2014-12-31 18.93 0.00 19.68
2014-09-30 22.21 0.00 23.90
2014-06-30 26.76 0.00 27.83
2014-03-31 29.40 0.00 29.91
2013-12-31 -12.08 11.91 0.01
2013-09-30 -11.70 11.48 0.02
2013-06-30 -11.19 10.94 0.02
2013-03-31 -10.12 10.16 0.05
2012-12-31 -10.12 10.16 0.05
  • Recro Pharma has negative shareholder equity (liabilities exceed assets), this is a more serious situation compared with a high debt level.
  • Irrelevant to check if Recro Pharma's debt level has increased considering it has negative shareholder equity.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Recro Pharma has less than a year of cash runway based on current free cash flow.
  • Recro Pharma has less than a year of cash runway if free cash flow continues to grow at historical rates of 92.5% each year.
X
Financial health checks
We assess Recro Pharma's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Recro Pharma has a total score of 1/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Recro Pharma's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Recro Pharma dividends.
If you bought €2,000 of Recro Pharma shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Recro Pharma's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Recro Pharma's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
BST:RAH Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 327 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

BST:RAH Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2019-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Recro Pharma has not reported any payouts.
  • Unable to verify if Recro Pharma's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Recro Pharma's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Recro Pharma has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Recro Pharma's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Recro Pharma afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Recro Pharma has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Recro Pharma's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Gerri Henwood
COMPENSATION $2,427,434
AGE 66
TENURE AS CEO 11.3 years
CEO Bio

Dr. Geraldine A. Henwood, also known as Gerri, Ph.D., has been the Chief Development Officer of Iomab-B at Actinium Pharmaceuticals, Inc. since September 2012. Dr. Henwood has been the Chief Executive Officer of Garnet Biotherapeutics, Inc. since November 2008. She has been the Chief Executive Officer, Director and President of RECRO Pharma, Inc. since 2008. She is a Venture Partner at SCP Vitalife. She is the Founder of Malvern Consulting Group and served as its President from 2006 to 2013. She more than 30 years' experience in product commercialization, clinical development and regulatory approval processes. She founded Auxilium Pharmaceuticals Inc., and served as its Chairman of the Board from July 1999 to April 2005, Chief Executive Officer from July 1999 to July 17, 2006, President from July 1999 to May 2004 and Interim President from March 2005 to July 17, 2006. She served as a Consultant at Auxilium Pharmaceuticals Inc. since July 17, 2006. She served as the Chief Executive Officer and President of Theorem Clinical Research, Inc., since April 1994. From 1985 to 1999, she served as the Chief Executive Officer at IBAH, which she founded in 1985. Prior to that, she served as Group Director of Marketing in the International Pharmaceutical Division at Smith Kline & French Laboratories, part of Glaxo SmithKline PLC. From April 1994 to 1999, she served as the President and Chief Executive Officer of Omnicare Clinical Research, Inc. Prior to that, she served in a variety of marketing, senior medical and regulatory positions at Smith Kline & French Laboratories. She began her career with Smith Kline & French in the Pharmaceutical Marketing Department. She serves as Director of Seachaid Pharmaceuticals, Inc. She serves as a Director of Antler Science Two Ltd. She has been a Director of Tetraphase Pharmaceuticals, Inc. since April 15, 2015 and Garnet Biotherapeutics Inc since November 2008. She served as a Director of Alkermes plc from September 16, 2011 to March 7, 2015. She served as a Director of Omnicare Clinical Research, Inc. She served as a Director of Auxilium Pharmaceuticals Inc. since July 1999 until 2006. She served as a Director of Genomics Collaborative, Inc. She served as a Director of Theorem Clinical Research, Inc., since July 1992. She served as a Director of MAP Pharmaceuticals, Inc. from June 2004 to March 1, 2013. She serves on the Board of Trustees of LaSalle Academy. Dr. Henwood holds a B.S. in Biology from Neuman College. She also holds a Ph.D.

CEO Compensation
  • Gerri's compensation has increased whilst company is loss making.
  • Gerri's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Recro Pharma management team in years:

3.3
Average Tenure
54
Average Age
  • The tenure for the Recro Pharma management team is about average.
Management Team

Gerri Henwood

TITLE
President
COMPENSATION
$2M
AGE
66
TENURE
11.3 yrs

Ryan Lake

TITLE
Chief Financial Officer
COMPENSATION
$784K
AGE
41
TENURE
1.3 yrs

Mike Celano

TITLE
COO & Corporate Secretary
COMPENSATION
$1M
AGE
59
TENURE
1.3 yrs

Randy Mack

TITLE
Senior VP of Development & Corporate Secretary
COMPENSATION
$685K
AGE
53
TENURE
11.3 yrs

Diane Myers

TITLE
Senior Vice President of Regulatory Affairs & Quality Assurance
AGE
54
TENURE
5.3 yrs

Stewart McCallum

TITLE
Chief Medical Officer
COMPENSATION
$1M
AGE
52
TENURE
3.3 yrs

Jyrki Mattila

TITLE
Executive Vice President of Business Development
AGE
63

John Harlow

TITLE
Executive Vice President of Commercial
TENURE
1.2 yrs
Board of Directors Tenure

Average tenure and age of the Recro Pharma board of directors in years:

5.1
Average Tenure
62
Average Age
  • The tenure for the Recro Pharma board of directors is about average.
Board of Directors

Wayne Weisman

TITLE
Chairman of the board
COMPENSATION
$210K
AGE
62
TENURE
11.3 yrs

Gerri Henwood

TITLE
President
COMPENSATION
$2M
AGE
66
TENURE
11.3 yrs

Win Churchill

TITLE
Independent Director
COMPENSATION
$191K
AGE
78
TENURE
11.3 yrs

Karen Flynn

TITLE
Independent Director
COMPENSATION
$200K
AGE
55
TENURE
3.6 yrs

Bryan Reasons

TITLE
Independent Director
COMPENSATION
$195K
AGE
51
TENURE
2.1 yrs

Bill Ashton

TITLE
Independent Director
COMPENSATION
$182K
AGE
67
TENURE
10.3 yrs

Al Altomari

TITLE
Independent Director
COMPENSATION
$192K
AGE
59
TENURE
5.1 yrs

Michael Berelowitz

TITLE
Independent Director
COMPENSATION
$190K
AGE
74
TENURE
5.1 yrs

Arnaud Ajdler

TITLE
Director
AGE
43
TENURE
0.1 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
24. May 18 Sell Broadfin Capital, LLC Company 24. May 18 24. May 18 -188,000 €5.12 €-932,375
X
Management checks
We assess Recro Pharma's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Recro Pharma has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Recro Pharma, Inc., a specialty pharmaceutical company, develops and commercializes products for hospital and related acute care settings. The company operates in two segments, Acute Care, and Contract Development and Manufacturing. Its lead product candidate includes injectable meloxicam, which completed pivotal phase III clinical trials for the treatment of post-operative pain. The company also develops early-stage product candidates, which include Dex-IN, an intranasal formulation of dexmedetomidine for use in clinical sedation; and two novel neuromuscular blocking agents and a related proprietary chemical reversal agent. In addition, it provides formulation and development services to develop and manufacture pharmaceutical products using proprietary delivery technologies and know-how for commercial partners. The company was formerly known as Recro Pharma I, Inc. and changed its name to Recro Pharma, Inc. in August 2008. Recro Pharma, Inc. was founded in 2007 and is based in Malvern, Pennsylvania.

Details
Name: Recro Pharma, Inc.
RAH
Exchange: BST
Founded: 2007
$163,472,790
21,990,735
Website: http://www.recropharma.com
Address: Recro Pharma, Inc.
490 Lapp Road,
Malvern,
Pennsylvania, 19355,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqCM REPH Common Stock Nasdaq Capital Market US USD 07. Mar 2014
BST RAH Common Stock Boerse-Stuttgart DE EUR 07. Mar 2014
Number of employees
Current staff
Staff numbers
255
Recro Pharma employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/21 21:40
End of day share price update: 2019/04/18 00:00
Last estimates confirmation: 2019/04/04
Last earnings filing: 2019/02/19
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.